Devices and methods for enrichment and alteration of circulating tumor cells and other particles

• US 20070026415A1
• Filed: 12/29/2005
• Published: 02/01/2007
• Est. Priority Date: 07/29/2005
• Status: Abandoned Application

• Current Assignee: Gpb Scientific, LLC, Mehmet Toner
• Original Assignee: Mehmet Toner
• Inventors: Toner, Mehmet, Fuchs, Martin, Huang, Yi-Shuian, Wang, Ying-Xin, Krueger, Neil
• Application Number:
  US11/323,946
• Publication Number:
  US 20070026415A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: B01L 2200/0647 Handling flowable solids, e.g. microscopic beads, cells, particles
• CPC Class Codes: B01L 2300/0816 Cards, e.g. flat sample carriers usually with flow in two horizontal directions
• CPC Class Codes: B01L 2300/0864 comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
• CPC Class Codes: B01L 2400/0409 centrifugal forces
• CPC Class Codes: B01L 2400/0472 Diffusion
• CPC Class Codes: B01L 2400/0487 fluid pressure, pneumatics
• CPC Class Codes: B01L 2400/086 using baffles or other fixed flow obstructions
• CPC Class Codes: B01L 3/502746 characterised by the means for controlling flow resistance, e.g. flow controllers, baffles B01L3/502738 takes precedence
• CPC Class Codes: B01L 3/502753 characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation separation in general B01D; microapparatus for analysis using electrophoresis G01N27/44791; sample preparation G01N1/28
• CPC Class Codes: B01L 3/502761 specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules investigating characteristics of particles G01N15/00
• CPC Class Codes: B82Y 10/00 Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: C12Q 2600/178 miRNA, siRNA or ncRNA
• CPC Class Codes: G01N 1/40 Concentrating samples
• CPC Class Codes: G01N 2035/00237 Handling microquantities of analyte, e.g. microvalves, capillary networks
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/5005 involving human or animal cells immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/574 : for cancer

Abstract

The invention features devices and methods for detecting, enriching, and analyzing circulating tumor cells and other particles. The invention further features methods of diagnosing a condition, e.g., cancer, in a subject by analyzing a cellular sample from the subject.

Claims

1. A method for diagnosing a condition in a subject, said method comprising the steps of:

a) introducing a cellular sample from said subject into a device comprising a channel comprising a structure that directs one or more first cells in a first direction to produce a first output sample enriched in said first cells and one or more second cells in a second direction to produce a second output sample enriched in said second cells;

b) analyzing said first output sample; and

c) diagnosing the presence or absence of said condition based on the results of step b).

2. The method of claim 1, wherein said device is configured to direct cells having a hydrodynamic size greater than 12 microns in said first direction, and cells having a hydrodynamic size less than or equal to 12 microns in said second direction.

3. The method of claim 1, wherein said device is configured to direct cells having a hydrodynamic size greater than 14 microns in said first direction, and cells having a hydrodynamic size less than or equal to 14 microns in said second direction.

4. The method of claim 1, wherein said device is configured to direct cells having a hydrodynamic size greater than or equal to 5 microns and less than or equal to 10 microns in said first direction, and cells having a hydrodynamic size greater than 10 microns in said second direction.

5. The method of claim 1, wherein said device is configured to direct cells having a hydrodynamic size greater than or equal to 4 microns and less than or equal to 8 microns in said first direction, and cells having a hydrodynamic size greater than 8 microns in said second direction.

6. The method of claim 1, wherein said first output sample comprises at least 90% of said first cells in said cellular sample.

7. The method of claim 1, further comprising repeating steps a) through c) one or more times with additional cellular samples from said subject.

8. The method of claim 7, wherein said cellular samples are obtained at regular intervals.

9. The method of claim 8, wherein said regular interval is one day, two days, three days, one week, two weeks, one month, two months, three months, six months, or one year.

10. The method of claim 1, wherein said first output sample is enriched in said first cells relative to said cellular sample by a factor of at least 1,000.

11. The method of claim 1, wherein said condition is a hematological condition, an inflammatory condition, an ischemic condition, a neoplastic condition, infection, trauma, endometriosis, or kidney failure.

12. The method of claim 11, wherein said neoplastic condition is selected from the group consisting of acute lymphoblastic leukemia, acute or chronic lymphocyctic or granulocytic tumor, acute myeloid leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoma, adrenal cancer, basal cell carcinoma, bone cancer, brain cancer, breast cancer, bronchi cancer, cervical dysplasia, chronic myelogenous leukemia, colon cancer, epidermoid carcinoma, Ewing'"'"'s sarcoma, gallbladder:

cancer, gallstone tumor, giant cell tumor, glioblastoma multiforma, hairy-cell tumor, head cancer, hyperplasia, hyperplastic comeal nerve tumor, in situ carcinoma, intestinal ganglioneuroma, islet cell tumor, Kaposi'"'"'s sarcoma, kidney cancer, larynx cancer, leiomyomater tumor, liver cancer, lung cancer, lymphomas, malignant carcinoid, malignant hypercalcemia, malignant melanomas, marfanoid habitus tumor, medullary carcinoma, metastatic skin carcinoma, mucosal neuromas, mycosis fungoide, myelodysplastic syndrome, myeloma, neck cancer, neural tissue cancer, neuroblastoma, osteogenic sarcoma, osteosarcoma, ovarian tumor, pancreas cancer, parathyroid cancer, pheochromocytoma, polycythemia vera, primary brain tumor, prostate cancer, rectum cancer, renal cell tumor, retinoblastoma, rhabdomyosarcoma, seminoma, skin cancer, small-cell lung tumor, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, thyroid cancer, topical skin lesion, veticulum cell sarcoma, and Wilm'"'"'s tumor.

13. The method of claim 1, wherein said cellular sample is less than 50 mL in volume.

14. The method of claim 1, wherein step b) comprises detecting the presence or absence of a cancer biomarker in said first output sample.

15. The method of claim 14, wherein said cancer biomarker is a polypeptide selected from Table 1, or a nucleic acid encoding said polypeptide.

16. The method of claim 1, wherein step b) comprises identifying the presence or absence of a nucleic acid associated with cancer.

17. The method of claim 16, wherein said nucleic acid comprises genomic DNA, mRNA, or microRNA.

18. The method of claim 1, wherein step b) comprises analyzing the expression pattern of a nucleic acid associated with cancer.

19. The method of claim 18, wherein said nucleic acid comprises genomic DNA, mRNA, or microRNA.

20. The method of claim 16, wherein said nucleic acid contains a mutation and encodes a polypeptide selected from Table 1.

21. The method of claim 1, wherein step b) comprises identifying the presence or absence of cells that have a cell surface marker associated with cancer.

22. The method of claim 21, wherein said cell surface marker is selected from the group consisting of EpCAM, E-Cadherin, Mucin-1, Cytokeratin 8, EGFR, and leukocyte associated receptor (LAR).

23. The method of claim 1, wherein step b) further comprises contacting said first output sample with a device comprising a surface with one or more binding moieties that selectively bind one or more cells from said first output sample.

24. The method of claim 23, wherein said cells from said first output sample comprise epithelial or neoplastic cells.

25. The method of claim 24, wherein said neoplastic cell type is associated with a cancer selected from the group consisting of acute lymphoblastic leukemia, acute or chronic lymphocyctic or granulocytic tumor, acute myeloid leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoma, adrenal cancer, basal cell carcinoma, bone cancer, brain cancer, breast cancer, bronchi cancer, cervical dysplasia, chronic myelogenous leukemia, colon cancer, epidermoid carcinoma, Ewing'"'"'s sarcoma, gallbladder cancer, gallstone tumor, giant cell tumor, glioblastoma multiforma, hairy-cell tumor, head cancer, hyperplasia, hyperplastic comeal nerve tumor, in situ carcinoma, intestinal ganglioneuroma, islet cell tumor, Kaposi'"'"'s sarcoma, kidney cancer, larynx cancer, leiomyomater tumor, liver cancer, lung cancer, lymphomas, malignant carcinoid, malignant hypercalcemia, malignant melanomas, marfanoid habitus tumor, medullary carcinoma, metastatic skin carcinoma, mucosal neuromas, mycosis fungoide, myelodysplastic syndrome, myeloma, neck cancer, neural tissue cancer, neuroblastoma, osteogenic sarcoma, osteosarcoma, ovarian tumor, pancreas cancer, parathyroid cancer, pheochromocytoma, polycythemia vera, primary brain tumor, prostate cancer, rectum cancer, renal cell tumor, retinoblastoma, rhabdomyosarcoma, seminoma, skin cancer, small-cell lung tumor, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, thyroid cancer, topical skin lesion, veticulum cell sarcoma, and Wilm'"'"'s tumor.

26. The method of claim 25, wherein said cancer is not thyroid cancer.

27. The method of claim 23, wherein said binding moieties comprise a polypeptide.

28. The method of claim 27, wherein said polypeptide comprises an antibody or fragment thereof.

29. The method of claim 28, wherein said antibody or fragment thereof is monoclonal.

30. The method of claim 29, wherein said monoclonal antibody or fragment thereof binds to EpCAM.

31. The method of claim 1, wherein said structure comprises an array of obstacles that form a network of gaps.

32. The method of claim 31, wherein said obstacles are capable of selectively capturing said first cells.

33. The method of claim 31, wherein said gaps between said obstacles are more than 15 microns, more than 20 microns, or less than 60 microns.

34. The method of claim 1, wherein said cellular sample comprises blood, sweat, tears, ear flow, sputum, lymph, bone marrow suspension, urine, saliva, semen, vaginal flow, cerebrospinal fluid, brain fluid, ascites, milk, secretions of the respiratory, intestinal or genitourinary tract, amniotic fluid, or a water sample.

35. The method of claim 1, wherein step b) comprises analyzing the size distribution of said first output sample.

36. The method of claim 1, wherein step b) comprises determining the number of said first cells.

64. The method of claim 1, wherein said channel comprises an array of obstacles forming a network of gaps, and wherein fluid flows through said gaps such that said fluid is divided unequally into a major flux and a minor flux.

37. A method for identifying a cell pattern associated with a condition of interest, said method comprising the steps of:

a) obtaining a cellular sample from each of a plurality of control subjects and a plurality of case subjects having said condition of interest;

b) enriching by size, from each said cellular sample, cells having a hydrodynamic size greater than 12 microns;

c) analyzing cells enriched in step b); and

d) performing an association study using the results obtained in step c).

39. The method of claim 37, wherein step c) comprises detecting RNA levels in said cells enriched in step b).

40. The method of claim 39, wherein said RNA comprises mRNA or microRNA.

41. The method of claim 37, said plurality of case subjects comprising at least 50 case subjects and said plurality of control subjects comprising at least 50 control subjects.

42. The method of claim 37, wherein step c) comprises determining the number of said cells enriched in step b).

43. The method of claim 42, wherein step c) utilizes a cellular characteristic selected from the group consisting of impedance, light absorption, light scattering, and capacitance.

44. The method of claim 37, wherein step c) comprises analyzing the size distribution of said cells enriched in step b).

45. The method of claim 44, wherein step c) comprises using a microscope, a cell counter, a magnet, a biocavity laser, a mass spectrometer, a PCR device, an RT-PCR device, a matrix, a microarray, or a hyperspectral imaging system in order to determine said size distribution.

46. The method of claim 37, wherein said cellular sample comprises blood, sweat, tears, ear flow, sputum, lymph, bone marrow suspension, urine, saliva, semen, vaginal flow, cerebrospinal fluid, brain fluid, ascites, milk, secretions of the respiratory, intestinal or genitourinary tract, amniotic fluid, or a water sample.

47. The method of claim 37, wherein step c) comprises determining the tissue or tissues of origin of said cells enriched in step b).

48. The method of claim 37, wherein step c) comprises identifying, from said cells enriched in step b), one or more epithelial cells, cancer cells, bone marrow cells, fetal cells, progenitor cells, stem cells, foam cells, mesenchymal cells, immune system cells, endothelial cells, endometrial cells, connective tissue cells, trophoblasts, bacteria, fungi, or pathogens.

49. The method of claim 37, wherein step e) comprises contacting said cells enriched in step b) with one or more binding moieties that selectively bind said first cells.

50. The method of claim 49, wherein said binding moieties comprise a polypeptide.

51. The method of claim 50, wherein said polypeptide comprises an antibody or fragment thereof.

52. The method of claim 51, wherein said antibody or fragment thereof is monoclonal.

53. The method of claim 52, wherein said monoclonal antibody or fragment thereof binds to EpCAM.

54. The method of claim 51, wherein said wherein said antibody or fragment thereof is selected from the group consisting of anti-Ber-Ep4, anti-EpCAM, anti-E-Cadherin, anti-Mucin-1, anti-Cytokeratin 8, and anti-CD34+.

55. The method of claim 37, wherein said device is configured to direct said cells having a hydrodynamic size greater than 12 microns in a first direction, and cells having a hydrodynamic size less than or equal to 12 microns in a second direction.

56. The method of claim 37, wherein said device selectively captures said cells enriched in step b).

38. A method for diagnosing a condition in a subject, said method comprising the steps of:

a) providing a cell pattern associated with said condition;

b) obtaining a cellular sample from said subject;

c) enriching by size, from said cellular sample, cells having a hydrodynamic size greater than 12 microns;

d) analyzing cells enriched in step c); and

e) diagnosing the presence or absence of said condition in said subject based on said cell pattern of step a) together with said analysis of step d).

57. A method for determining the efficacy of a drug treatment administered to a subject, said method comprising the steps of:

a) obtaining a first cellular sample from said subject before said treatment;

b) introducing said first cellular sample into a device comprising a channel comprising a structure that directs one or more first cells in a first direction to produce a first output sample enriched in said first cells and one or more second cells in a second direction to produce a second output sample enriched in said second cells;

c) analyzing said first output sample;

d) obtaining a second cellular sample from said subject concurrently with or subsequent to said drug treatment;

e) repeating steps b) and c) for said second cellular sample; and

f) comparing the results of step c) for said first cellular sample and said second cellular sample,

wherein said comparing determines said efficacy of said drug treatment.

58. The method of claim 57, wherein said device is configured to direct cells having a hydrodynamic size greater than 12 microns in said first direction, and cells having a hydrodynamic size less than or equal to 12 microns in said second direction.

59. The method of claim 57, wherein said device is configured to direct cells having a hydrodynamic size greater than or equal to 6 microns and less than or equal to 12 microns in said first direction, and cells having a hydrodynamic size less than 6 microns or cells having a hydrodynamic size greater than 12 microns in said second direction.

60. The method of claim 57, wherein step c) comprises detecting RNA levels in said first cells from said first cellular sample or said second cellular sample.

61. The method of claim 60, wherein said RNA comprises mRNA or microRNA.

62. The method of claim 57, wherein step c) comprises determining the number of said first cells from said first cellular sample or said second cellular sample.

63. The method of claim 57, wherein step d) comprises identifying, from said first cells from said first cellular sample or said second cellular sample, one or more epithelial cells, cancer cells, bone marrow cells, fetal cells, progenitor cells, stem cells, foam cells, mesenchymal cells, immune system cells, endothelial cells, endometrial cells, connective tissue cells, trophoblasts, bacteria, fungi, or pathogens.